For the PDAC cohort (n = 38), an ORR of 21.1% and a DCR of 84.25% in a heavily pretreated population were noted.221 Sotorasib showed sustained clinical benefit across all levels of PD-L1 expression and tumor mutational burden (TMB) and across different comutation profiles. This evidence concerns the gene CD274 and neoplasm.